Selected article for: "ace enzyme and acute respiratory distress syndrome"
Author: Yiğenoğlu, Tuğçe Nur; Başcı, Semih; Şahin, Derya; Ulaş, Turgay; Dal, Mehmet Sinan; Korkmaz, Serdal; Hacıbekiroğlu, Tuba; Namdaroğlu, Sinem; Erkurt, Mehmet Ali; Turgut, Burhan; Altuntaş, Fevzi
Title: Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients
  • Cord-id: if40hlvg
  • Document date: 2021_8_17
    • ID: if40hlvg
    Snippet: SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARS-CoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the r
    Document: SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARS-CoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.

    Search related documents:
    Co phrase search for related documents
    • abnormal ratio and acute respiratory syndrome coronavirus: 1, 2, 3
    • absent low and acute ards respiratory distress syndrome: 1
    • absent low and acute inflammatory: 1
    • absent low and acute respiratory distress syndrome: 1, 2
    • absent low and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absent low and acute sars cov respiratory syndrome cov: 1
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immune cell: 1, 2
    • acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
    • acute cardiac injury and adaptive innate: 1
    • acute inflammatory and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute inflammatory and adaptive innate immune cell: 1
    • acute inflammatory and administration route: 1, 2, 3
    • acute respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and adaptive innate immune cell: 1, 2, 3
    • acute respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and adaptive innate immune cell: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20